KLF15 was reduced in adriamycin (ADR)-treated, lipopolysaccharide (LPS)-treated or high glucose (HG)-treated podocytes in vitro
(A) KLF15 mRNA expression was measured in ADR-, LPS- or HG-treated podocytes using RT-qPCR analysis. (B) Similarly, the protein expression of KLF15 was analyzed in cultured podocytes treated with ADR (0.25 μg/ml), LPS (100 μg/ml) or HG (30 mmol/l) using Western blot analysis. Data were from at least three independent experiments; *P<0.05, **P<0.01 and ***P<0.001 vs. controls.